{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:33:00Z","timestamp":1780043580922,"version":"3.53.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018822","name":"Western Sydney University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018822","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40265-025-02279-6","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:37:49Z","timestamp":1769848669000},"page":"321-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-8194","authenticated-orcid":false,"given":"Penelope","family":"Fotheringham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3125-8253","authenticated-orcid":false,"given":"Richard G","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6874-4506","authenticated-orcid":false,"given":"Debra","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-0761","authenticated-orcid":false,"given":"David","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"2279_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155217","volume":"133","author":"C Boutari","year":"2022","unstructured":"Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. https:\/\/doi.org\/10.1016\/j.metabol.2022.155217.","journal-title":"Metabolism"},{"key":"2279_CR2","unstructured":"Australian Institute of Health and Welfare. Australia\u2019s mothers and babies [Internet]. Canberra: AIHW; 2025. https:\/\/www.aihw.gov.au\/reports\/mothers-babies\/australias-mothers-babies. Accessed 12 Dec 2025."},{"key":"2279_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13310","volume":"22","author":"CL Harrison","year":"2021","unstructured":"Harrison CL, Teede H, Khan N, Lim S, Chauhan A, Drakeley S, et al. Weight management across preconception, pregnancy, and postpartum: a systematic review and quality appraisal of international clinical practice guidelines. Obes Rev. 2021;22:e13310. https:\/\/doi.org\/10.1111\/obr.13310.","journal-title":"Obes Rev"},{"key":"2279_CR4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1001\/jama.2017.3635","volume":"317","author":"RF Goldstein","year":"2017","unstructured":"Goldstein RF, Abell SK, Ranasinha S, Misso M, Boyle JA, Black MH, et al. Association of gestational weight gain with maternal and infant outcomes: a systematic review and meta-analysis. JAMA. 2017;317:2207. https:\/\/doi.org\/10.1001\/jama.2017.3635.","journal-title":"JAMA"},{"key":"2279_CR5","doi-asserted-by":"publisher","unstructured":"The American College of Obstetricians and Gynecologists. Committee Opinion No. 548: Weight Gain During Pregnancy. Obstet Gynecol. 2013;121:210\u20132. https:\/\/doi.org\/10.1097\/01.AOG.0000425668.87506.4c.","DOI":"10.1097\/01.AOG.0000425668.87506.4c"},{"key":"2279_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11154-012-9231-7","volume":"14","author":"DMJ Muris","year":"2013","unstructured":"Muris DMJ, Houben AJHM, Schram MT, Stehouwer CDA. Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. Rev Endocr Metab Disord. 2013;14:29\u201338. https:\/\/doi.org\/10.1007\/s11154-012-9231-7.","journal-title":"Rev Endocr Metab Disord"},{"key":"2279_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071681","volume":"12","author":"J Go\u0142acki","year":"2022","unstructured":"Go\u0142acki J, Matuszek M, Matyjaszek-Matuszek B. Link between insulin resistance and obesity-from diagnosis to treatment. Diagnostics. 2022;12:1681. https:\/\/doi.org\/10.3390\/diagnostics12071681.","journal-title":"Diagnostics"},{"key":"2279_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1055\/s-0039-1698831","volume":"38","author":"NW Carris","year":"2021","unstructured":"Carris NW, Nwabuobi CK, He W, Bullers K, Wilson RE, Louis JM, et al. Review of prediabetes and hypertensive disorders of pregnancy. Am J Perinatol. 2021;38:428\u201335. https:\/\/doi.org\/10.1055\/s-0039-1698831.","journal-title":"Am J Perinatol"},{"key":"2279_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/2633494120986544","volume":"15","author":"JA Grieger","year":"2021","unstructured":"Grieger JA, Hutchesson MJ, Cooray SD, Bahri Khomami M, Zaman S, Segan L, et al. A review of maternal overweight and obesity and its impact on cardiometabolic outcomes during pregnancy and postpartum. Ther Adv Reprod Health. 2021;15:2633494120986544. https:\/\/doi.org\/10.1177\/2633494120986544.","journal-title":"Ther Adv Reprod Health"},{"key":"2279_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02184-4","volume":"23","author":"CK Kramer","year":"2024","unstructured":"Kramer CK, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, et al. Postpartum weight retention and the early evolution of cardiovascular risk over the first 5 years after pregnancy. Cardiovasc Diabetol. 2024;23:101. https:\/\/doi.org\/10.1186\/s12933-024-02184-4.","journal-title":"Cardiovasc Diabetol"},{"key":"2279_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2337\/dc12-0741","volume":"36","author":"MH Black","year":"2013","unstructured":"Black MH, Sacks DA, Xiang AH, Lawrence JM. The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth. Diabetes Care. 2013;36:56\u201362. https:\/\/doi.org\/10.2337\/dc12-0741.","journal-title":"Diabetes Care"},{"key":"2279_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2563","author":"M Persson","year":"2017","unstructured":"Persson M, Cnattingius S, Villamor E, S\u00f6derling J, Pasternak B, Stephansson O, et al. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ. 2017. https:\/\/doi.org\/10.1136\/bmj.j2563.","journal-title":"BMJ"},{"key":"2279_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/s-0029-1237424","volume":"27","author":"P Wadhwa","year":"2009","unstructured":"Wadhwa P, Buss C, Entringer S, Swanson J. Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Semin Reprod Med. 2009;27:358\u201368. https:\/\/doi.org\/10.1055\/s-0029-1237424.","journal-title":"Semin Reprod Med"},{"key":"2279_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2337\/diab.29.12.1023","volume":"29","author":"N Freinkel","year":"1980","unstructured":"Freinkel N. Banting Lecture 1980. Of pregnancy and progeny. Diabetes. 1980;29:1023\u201335. https:\/\/doi.org\/10.2337\/diab.29.12.1023.","journal-title":"Diabetes"},{"key":"2279_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.puhe.2011.11.014","volume":"126","author":"DJP Barker","year":"2012","unstructured":"Barker DJP. Developmental origins of chronic disease. Public Health. 2012;126:185\u20139. https:\/\/doi.org\/10.1016\/j.puhe.2011.11.014.","journal-title":"Public Health"},{"key":"2279_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41591-024-03356-1","volume":"31","author":"LC Kusinski","year":"2025","unstructured":"Kusinski LC, Jones D, Atta N, Turner E, Smith S, Oude Griep LM, et al. Reduced-energy diet in women with gestational diabetes: the dietary intervention in gestational diabetes DiGest randomised clinical trial. Nat Med. 2025;31:514\u201323. https:\/\/doi.org\/10.1038\/s41591-024-03356-1.","journal-title":"Nat Med"},{"key":"2279_CR17","doi-asserted-by":"publisher","first-page":"137.e1","DOI":"10.1016\/j.ajog.2014.02.004","volume":"211","author":"PM Catalano","year":"2014","unstructured":"Catalano PM, Mele L, Landon MB, Ramin SM, Reddy UM, Casey B, et al. Inadequate weight gain in overweight and obese pregnant women: what is the effect on fetal growth? Am J Obstet Gynecol. 2014;211:137.e1-137.e7. https:\/\/doi.org\/10.1016\/j.ajog.2014.02.004.","journal-title":"Am J Obstet Gynecol"},{"key":"2279_CR18","doi-asserted-by":"publisher","unstructured":"Denison F, Aedla N, Keag O, Hor K, Reynolds R, Milne A, et al. Care of Women with Obesity in Pregnancy: Green\u2010top Guideline No. 72. BJOG Int J Obstet Gynaecol [Internet]. 2019 [cited 2025 Aug 14];126. https:\/\/doi.org\/10.1111\/1471-0528.15386.","DOI":"10.1111\/1471-0528.15386"},{"key":"2279_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ijgo.13334","volume":"151","author":"FM McAuliffe","year":"2020","unstructured":"McAuliffe FM, Killeen SL, Jacob CM, Hanson MA, Hadar E, McIntyre HD, et al. Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO Pregnancy and Non-Communicable Diseases Committee: a FIGO (International Federation of Gynecology and Obstetrics) guideline. Int J Gynecol Obstet. 2020;151:16\u201336. https:\/\/doi.org\/10.1002\/ijgo.13334.","journal-title":"Int J Gynecol Obstet"},{"key":"2279_CR20","unstructured":"RANZCOG. Management of Obesity in Pregnancy [Internet]. 2022. https:\/\/ranzcog.edu.au\/wp-content\/uploads\/Management-Obesity-Pregnancy.pdf. Accessed 12 Dec 2025."},{"key":"2279_CR21","doi-asserted-by":"publisher","first-page":"1364503","DOI":"10.3389\/fendo.2024.1364503","volume":"15","author":"MA Roomy","year":"2024","unstructured":"Roomy MA, Hussain K, Behbehani HM, Abu-Farha J, Al-Harris R, Ambi AM, et al. Therapeutic advances in obesity management: an overview of the therapeutic interventions. Front Endocrinol. 2024;15:1364503. https:\/\/doi.org\/10.3389\/fendo.2024.1364503.","journal-title":"Front Endocrinol"},{"key":"2279_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","volume":"401","author":"CM Perdomo","year":"2023","unstructured":"Perdomo CM, Cohen RV, Sumithran P, Cl\u00e9ment K, Fr\u00fchbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401:1116\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(22)02403-5.","journal-title":"Lancet"},{"key":"2279_CR23","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomised clinical trial. JAMA. 2021;325:1414. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"key":"2279_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"key":"2279_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin W-Y, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomised clinical trial. JAMA. 2024;331:38. https:\/\/doi.org\/10.1001\/jama.2023.24945.","journal-title":"JAMA"},{"key":"2279_CR26","doi-asserted-by":"publisher","unstructured":"Pondugula N, Culhane JF, Lundsberg LS, Partridge C, Merriam AA. Gestational Weight Gain and Hypertensive Disorders of Pregnancy With Prepregnancy and Early Pregnancy Glucagon-Like Peptide-1 Receptor Agonist Exposure. Obstet Gynecol [Internet]. 2025 [cited 2025 Dec 8]. https:\/\/doi.org\/10.1097\/AOG.0000000000005995.","DOI":"10.1097\/AOG.0000000000005995"},{"key":"2279_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20951","author":"J Maya","year":"2025","unstructured":"Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, et al. Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.20951.","journal-title":"JAMA"},{"key":"2279_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1509819","volume":"374","author":"A Syngelaki","year":"2016","unstructured":"Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al. Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med. 2016;374:434\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1509819.","journal-title":"N Engl J Med"},{"key":"2279_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(18)30310-3","volume":"7","author":"JM Dodd","year":"2019","unstructured":"Dodd JM, Louise J, Deussen AR, Grivell RM, Dekker G, McPhee AJ, et al. Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:15\u201324. https:\/\/doi.org\/10.1016\/S2213-8587(18)30310-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2279_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/dc12-1097","volume":"36","author":"HL Barrett","year":"2013","unstructured":"Barrett HL, Gatford KL, Houda CM, De Blasio MJ, McIntyre HD, Callaway LK, et al. Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the Metformin in Gestational Diabetes (MiG) Trial. Diabetes Care. 2013;36:529\u201336. https:\/\/doi.org\/10.2337\/dc12-1097.","journal-title":"Diabetes Care"},{"key":"2279_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S2352-4642(18)30385-7","volume":"3","author":"LGE Hanem","year":"2019","unstructured":"Hanem LGE, Salvesen \u00d8, Juliusson PB, Carlsen SM, Nossum MCF, Vaage M\u00d8, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5\u201310 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019;3:166\u201374. https:\/\/doi.org\/10.1016\/S2352-4642(18)30385-7.","journal-title":"Lancet Child Adolesc Health"},{"key":"2279_CR32","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2023.19869","volume":"330","author":"F Dunne","year":"2023","unstructured":"Dunne F, Newman C, Alvarez-Iglesias A, Ferguson J, Smyth A, Browne M, et al. Early metformin in gestational diabetes: a randomised clinical trial. JAMA. 2023;330:1547. https:\/\/doi.org\/10.1001\/jama.2023.19869.","journal-title":"JAMA"},{"key":"2279_CR33","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S2213-8587(15)00219-3","volume":"3","author":"C Chiswick","year":"2015","unstructured":"Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3:778\u201386. https:\/\/doi.org\/10.1016\/S2213-8587(15)00219-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2279_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2017-000456","volume":"6","author":"JA Rowan","year":"2018","unstructured":"Rowan JA, Rush EC, Plank LD, Lu J, Obolonkin V, Coat S, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7\u20139 years of age. BMJ Open Diabetes Res Care. 2018;6:e000456. https:\/\/doi.org\/10.1136\/bmjdrc-2017-000456.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2279_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/j.1552-4604.1996.tb04230.x","volume":"36","author":"AT Melia","year":"1996","unstructured":"Melia AT, Koss\u2010Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36:647\u201353. https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04230.x.","journal-title":"J Clin Pharmacol"},{"key":"2279_CR36","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1016\/j.orcp.2013.11.008","volume":"8","author":"BAJ K\u00e4ll\u00e9n","year":"2014","unstructured":"K\u00e4ll\u00e9n BAJ. Antiobesity drugs in early pregnancy and congenital malformations in the offspring. Obes Res Clin Pract. 2014;8:e571\u20136. https:\/\/doi.org\/10.1016\/j.orcp.2013.11.008.","journal-title":"Obes Res Clin Pract"},{"key":"2279_CR37","doi-asserted-by":"publisher","first-page":"e3533","DOI":"10.1210\/clinem\/dgab340","volume":"106","author":"Z Wang","year":"2021","unstructured":"Wang Z, Zhao J, Ma X, Sun Y, Hao G, Yang A, et al. Effect of orlistat on live birth rate in overweight or obese women undergoing IVF-ET: a randomised clinical trial. J Clin Endocrinol Metab. 2021;106:e3533\u201345. https:\/\/doi.org\/10.1210\/clinem\/dgab340.","journal-title":"J Clin Endocrinol Metab"},{"key":"2279_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mcna.2017.08.010","volume":"102","author":"KH Saunders","year":"2018","unstructured":"Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. Med Clin North Am. 2018;102:135\u201348. https:\/\/doi.org\/10.1016\/j.mcna.2017.08.010.","journal-title":"Med Clin North Am"},{"key":"2279_CR39","unstructured":"FDA. XENICAL (orlistat) drug information [Internet]. FDA; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020766s038lbl.pdf. Accessed 12 Dec 2025."},{"key":"2279_CR40","doi-asserted-by":"publisher","first-page":"83.e1","DOI":"10.1016\/j.ajog.2019.07.037","volume":"222","author":"CV Towers","year":"2020","unstructured":"Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol. 2020;222:83.e1-83.e8. https:\/\/doi.org\/10.1016\/j.ajog.2019.07.037.","journal-title":"Am J Obstet Gynecol"},{"key":"2279_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/ADM.0000000000001293","volume":"18","author":"EM Wachman","year":"2024","unstructured":"Wachman EM, Saia K, Bressler J, Werler M, Carter G, Jones HE. Case series of individuals treated with naltrexone during pregnancy for opioid and\/or alcohol use disorder. J Addict Med. 2024;18:288\u201392. https:\/\/doi.org\/10.1097\/ADM.0000000000001293.","journal-title":"J Addict Med"},{"key":"2279_CR42","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ajog.2004.09.027","volume":"192","author":"B Chun-Fai-Chan","year":"2005","unstructured":"Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932\u20136. https:\/\/doi.org\/10.1016\/j.ajog.2004.09.027.","journal-title":"Am J Obstet Gynecol"},{"key":"2279_CR43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ntr\/nty055","volume":"21","author":"E Turner","year":"2019","unstructured":"Turner E, Jones M, Vaz LR, Coleman T. Systematic review and meta-analysis to assess the safety of bupropion and varenicline in pregnancy. Nicotine Tob Res. 2019;21:1001\u201310. https:\/\/doi.org\/10.1093\/ntr\/nty055.","journal-title":"Nicotine Tob Res"},{"key":"2279_CR44","unstructured":"TGA. Phentermine Sandoz Australian Product Information [Internet]. 2025. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2022-PI-01212-1&d=20250817172310101&d=20250819172310101. Accessed 12 Dec 2025."},{"key":"2279_CR45","doi-asserted-by":"publisher","unstructured":"Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Pennell PB, et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology [Internet]. 2018 [cited 2025 Aug 14];90. https:\/\/doi.org\/10.1212\/WNL.0000000000004857.","DOI":"10.1212\/WNL.0000000000004857"},{"key":"2279_CR46","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2309359","volume":"390","author":"S Hern\u00e1ndez-D\u00edaz","year":"2024","unstructured":"Hern\u00e1ndez-D\u00edaz S, Straub L, Bateman BT, Zhu Y, Mogun H, Wisner KL, et al. Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure. N Engl J Med. 2024;390:1069\u201379. https:\/\/doi.org\/10.1056\/NEJMoa2309359.","journal-title":"N Engl J Med"},{"key":"2279_CR47","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31:951\u201362. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med"},{"key":"2279_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/jama.2024.10333","volume":"332","author":"E Harris","year":"2024","unstructured":"Harris E. Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable. JAMA. 2024;332:8. https:\/\/doi.org\/10.1001\/jama.2024.10333.","journal-title":"JAMA"},{"key":"2279_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1215356","volume":"14","author":"DRP Muller","year":"2023","unstructured":"Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol. 2023;14:1215356. https:\/\/doi.org\/10.3389\/fendo.2023.1215356.","journal-title":"Front Endocrinol"},{"key":"2279_CR50","unstructured":"TGA. Ozempic (Semaglutide) Australian Product Information [Internet]. 2025. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-semaglutide-201030-pi.pdf. Accessed 12 Dec 2025."},{"key":"2279_CR51","unstructured":"TGA. Victoza (Liraglutide) Australian Product Information [Internet]. 2025. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-liraglutide-190429-pi.pdf. Accessed 12 Dec 2025."},{"key":"2279_CR52","doi-asserted-by":"publisher","first-page":"E268","DOI":"10.1152\/ajpendo.00361.2023","volume":"326","author":"L Qiao","year":"2024","unstructured":"Qiao L, Lu C, Zang T, Dzyuba B, Shao J. Maternal GLP-1 receptor activation inhibits fetal growth. Am J Physiol-Endocrinol Metab. 2024;326:E268\u201376. https:\/\/doi.org\/10.1152\/ajpendo.00361.2023.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"2279_CR53","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1111\/dom.16437","volume":"27","author":"CH Parker","year":"2025","unstructured":"Parker CH, Slattery C, Brennan DJ, Le Roux CW. Glucagon\u2010like peptide 1 ( glp \u20101) receptor agonists\u2019 use during pregnancy: safety data from regulatory clinical trials. Diabetes Obes Metab. 2025;27:4102\u20138. https:\/\/doi.org\/10.1111\/dom.16437.","journal-title":"Diabetes Obes Metab"},{"key":"2279_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","volume":"184","author":"CE Cesta","year":"2024","unstructured":"Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024;184:144. https:\/\/doi.org\/10.1001\/jamainternmed.2023.6663.","journal-title":"JAMA Intern Med"},{"key":"2279_CR55","doi-asserted-by":"publisher","unstructured":"Hviid K, Banasik K, Mortensen LH, Madsbad S, Geiker NRW, Westergaard D, et al. P-779 GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications\u2014a nationwide cohort study. Hum Reprod. 2024;39:deae108.041. https:\/\/doi.org\/10.1093\/humrep\/deae108.041.","DOI":"10.1093\/humrep\/deae108.041"},{"key":"2279_CR56","doi-asserted-by":"publisher","first-page":"116.e1","DOI":"10.1016\/j.ajog.2025.01.019","volume":"233","author":"MR Imbroane","year":"2025","unstructured":"Imbroane MR, LeMoine F, Nau CT. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am J Obstet Gynecol. 2025;233:116.e1-116.e7. https:\/\/doi.org\/10.1016\/j.ajog.2025.01.019.","journal-title":"Am J Obstet Gynecol"},{"key":"2279_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amjcard.2025.03.013","volume":"246","author":"M Hanif","year":"2025","unstructured":"Hanif M, Hays AG, Nagarajan JS, Sah SP, Weinstock RS, Taub CC. Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes. Am J Cardiol. 2025;246:10\u20133. https:\/\/doi.org\/10.1016\/j.amjcard.2025.03.013.","journal-title":"Am J Cardiol"},{"key":"2279_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083550","volume":"14","author":"K Dao","year":"2024","unstructured":"Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024;14:e083550. https:\/\/doi.org\/10.1136\/bmjopen-2023-083550.","journal-title":"BMJ Open"},{"key":"2279_CR59","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/bcp.16354","volume":"91","author":"J Zhou","year":"2025","unstructured":"Zhou J, Wei Z, Lai W, Liu M, Wu X. The safety profile of usage of glucagon\u2010like peptide\u20101 receptor agonists in pregnancy: a pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2025;91:1272\u201380. https:\/\/doi.org\/10.1111\/bcp.16354.","journal-title":"Br J Clin Pharmacol"},{"key":"2279_CR60","unstructured":"Ivani\u0161evi\u0107 M, Herman M, Horvati\u010dek M, Vu\u010di\u0107 Lovren\u010di\u0107 M, \u0110elmi\u0161 J. Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report. Gynaecol Perinatol J Gynaecol Perinatol Reprod Med Ultrason Diagn. Hrvatsko dru\u0161tvo za ginekologiju i opstetriciju i Hrvatsko dru\u0161tvo za. 2018;27:70\u20132."},{"key":"2279_CR61","doi-asserted-by":"publisher","unstructured":"Morton A, He J. Pregnancy outcomes following first trimester exposure to semaglutide. Obstet Med. 2025;1753495X251346330. https:\/\/doi.org\/10.1177\/1753495X251346330.","DOI":"10.1177\/1753495X251346330"},{"key":"2279_CR62","unstructured":"Ozen B, Colak O, Gultekin O, Yananli H, Goren M, Akici A. Evaluation of exposures of glucagon-like peptide-1 receptor agonists during pregnancy. Case series from a university\u2019s teratology information service. E-poster 6. 36th ENTIS Conference, ENTIS2025 conference, Thessaloniki, Greece. 2025. https:\/\/www.36entis2025.com. Accessed 12 Dec 2025."},{"key":"2279_CR63","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/psp4.13195","volume":"13","author":"C Gong","year":"2024","unstructured":"Gong C, Bertagnolli LN, Boulton DW, Coppola P. A literature review of drug transport mechanisms during lactation. CPT Pharmacom Syst Pharmacol. 2024;13:1870\u201380. https:\/\/doi.org\/10.1002\/psp4.13195.","journal-title":"CPT Pharmacom Syst Pharmacol"},{"key":"2279_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/nu16172886","volume":"16","author":"H Diab","year":"2024","unstructured":"Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients. 2024;16:2886. https:\/\/doi.org\/10.3390\/nu16172886.","journal-title":"Nutrients"},{"key":"2279_CR65","doi-asserted-by":"publisher","unstructured":"Thompson J, Diab H, Datta P, Krutsch K. Tirzepatide (Zepbound) in human milk during periods of maternal dosing [Internet]. SSRN; 2025 [cited 2025 Dec 8]. https:\/\/doi.org\/10.2139\/ssrn.5387250.","DOI":"10.2139\/ssrn.5387250"},{"key":"2279_CR66","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"2279_CR67","unstructured":"Centre, Uppsala Monitoring. The Global Medicines Safety Database [Internet]. 2025. https:\/\/who-umc.org\/vigibase-data-access\/about-vigibase\/. Accessed 12 Dec 2025."},{"key":"2279_CR68","unstructured":"European Medicines Agency (EMA). EudraVigilance [Internet]. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance. Accessed 12 Dec 2025."},{"key":"2279_CR69","unstructured":"FDA adverse event reporting system database FAERs [Internet]. 2025. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers-database. Accessed 12 Dec 2025."},{"key":"2279_CR70","unstructured":"Womens mental health registry bupropion for depression [Internet]. 2025. https:\/\/womensmentalhealth.org\/research\/pregnancyregistry\/. Accessed 12 Dec 2025."},{"key":"2279_CR71","unstructured":"The North American Pregnancy Registry [Internet]. 2025. https:\/\/www.aedpregnancyregistry.org\/medications\/. Accessed 12 Dec 2025."},{"key":"2279_CR72","unstructured":"Information for Patients | Wegovy Pregnancy Registry. [Internet]. 2025. https:\/\/wegovypregnancyregistry.com\/patients. Accessed 12 Dec 2025."},{"key":"2279_CR73","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-0042-1748190","volume":"40","author":"E Dorney","year":"2022","unstructured":"Dorney E, Boyle JA, Walker R, Hammarberg K, Musgrave L, Schoenaker D, et al. A systematic review of clinical guidelines for preconception care. Semin Reprod Med. 2022;40:157\u201369. https:\/\/doi.org\/10.1055\/s-0042-1748190.","journal-title":"Semin Reprod Med"},{"key":"2279_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16101310","volume":"16","author":"A Boianelli","year":"2024","unstructured":"Boianelli A, Nordell P, Earl J, Naylor J, Hornigold D, Jansson L\u00f6fmark R, et al. Establishing a relationship between in vitro potency in cell-based assays and clinical efficacious concentrations for approved GLP-1 receptor agonists. Pharmaceutics. 2024;16:1310. https:\/\/doi.org\/10.3390\/pharmaceutics16101310.","journal-title":"Pharmaceutics"},{"key":"2279_CR75","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","volume":"55","author":"JS Geiser","year":"2016","unstructured":"Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55:625\u201334. https:\/\/doi.org\/10.1007\/s40262-015-0338-3.","journal-title":"Clin Pharmacokinet"},{"key":"2279_CR76","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bcp.13135","volume":"83","author":"B Cirincione","year":"2017","unstructured":"Cirincione B, Mager DE. Population pharmacokinetics of exenatide. Br J Clin Pharmacol. 2017;83:517\u201326. https:\/\/doi.org\/10.1111\/bcp.13135.","journal-title":"Br J Clin Pharmacol"},{"key":"2279_CR77","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1124\/dmd.110.034066","volume":"38","author":"M Malm-Erjef\u00e4lt","year":"2010","unstructured":"Malm-Erjef\u00e4lt M, Bj\u00f8rnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38:1944\u201353. https:\/\/doi.org\/10.1124\/dmd.110.034066.","journal-title":"Drug Metab Dispos"},{"key":"2279_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","volume":"104","author":"L Jensen","year":"2017","unstructured":"Jensen L, Helleberg H, Roffel A, van Lier JJ, Bj\u00f8rnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31\u201341. https:\/\/doi.org\/10.1016\/j.ejps.2017.03.020.","journal-title":"Eur J Pharm Sci"},{"key":"2279_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314. https:\/\/doi.org\/10.1016\/j.molmet.2018.09.009.","journal-title":"Mol Metab"},{"key":"2279_CR80","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/TEN.0b013e3181a5875e","volume":"19","author":"J Williams","year":"2009","unstructured":"Williams J, Pomeroy NE, Pop-Busui R, Lash R, Douyon L, Chames M, et al. Case report: exenatide use during pregnancy. The Endocrinologist. 2009;19:119\u201321. https:\/\/doi.org\/10.1097\/TEN.0b013e3181a5875e.","journal-title":"The Endocrinologist."},{"key":"2279_CR81","doi-asserted-by":"publisher","unstructured":"Greco D. Normal pregnancy outcome after first\u2010trimester exposure to liraglutide in a woman with Type 2 diabetes. Diabet Med [Internet]. 2015 [cited 2025 Aug 20];32. https:\/\/doi.org\/10.1111\/dme.12726.","DOI":"10.1111\/dme.12726"},{"key":"2279_CR82","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44644","volume":"15","author":"A Alghamdi","year":"2023","unstructured":"Alghamdi A, Alsaeddi A, Malki H, Alsaedi A. A case report of a pregnant woman with type 2 diabetes mellitus using dulaglutide during the first trimester of pregnancy. Cureus. 2023;15:e44644. https:\/\/doi.org\/10.7759\/cureus.44644.","journal-title":"Cureus"},{"key":"2279_CR83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00592-022-01954-4","volume":"60","author":"S Burlina","year":"2023","unstructured":"Burlina S, Dalfr\u00e0 MG, Caprino R, Lapolla A. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus. Acta Diabetol. 2023;60:137\u20138. https:\/\/doi.org\/10.1007\/s00592-022-01954-4.","journal-title":"Acta Diabetol"},{"key":"2279_CR84","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/ijgo.15092","volume":"163","author":"K Skov","year":"2023","unstructured":"Skov K, Mandic IN, Nyborg KM. Semaglutide and pregnancy. Int J Gynaecol Obstet. 2023;163:699\u2013700. https:\/\/doi.org\/10.1002\/ijgo.15092.","journal-title":"Int J Gynaecol Obstet"},{"key":"2279_CR85","doi-asserted-by":"publisher","unstructured":"Wajtryt O, Dedecjus M. Pregnancy after exposure to GLP-1 receptor agonists. A case report and literature review. Endocr Abstr [Internet]. 2023 [cited 2025 Aug 20]. https:\/\/doi.org\/10.1530\/endoabs.90.EP532.","DOI":"10.1530\/endoabs.90.EP532"},{"key":"2279_CR86","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2174\/0118715303252109231023115112","volume":"24","author":"\u015eE Do\u011fan","year":"2024","unstructured":"Do\u011fan \u015eE, Ku\u015fkonmaz \u015eM, Koc G, Aypar E, \u00c7ulha C. Case series: exposure to glucagon-like peptide-1 receptor agonist in the first trimester of pregnancy in two siblings. Endocr Metab Immune Disord Drug Targets. 2024;24:1237\u20139. https:\/\/doi.org\/10.2174\/0118715303252109231023115112.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2279_CR87","doi-asserted-by":"publisher","first-page":"749","DOI":"10.63278\/jicrcr.vi.2000","volume":"7","author":"A Alghamdi","year":"2024","unstructured":"Alghamdi A, Alqurashi J, Malki H, AlNozha SS, Alsaeddi A, Alsaedi A. Empagliflozin, Dulaglutide, and Atorvastatin during 1st weeks of pregnancy: a case report. J Int Crisis Risk Commun Res. 2024;7:749\u201352. https:\/\/doi.org\/10.63278\/jicrcr.vi.2000.","journal-title":"J Int Crisis Risk Commun Res."},{"key":"2279_CR88","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00592-024-02331-z","volume":"61","author":"M Molteni","year":"2024","unstructured":"Molteni M, Lodigiani S, Teliti M, Rotondi M, Guazzoni V. Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy. Acta Diabetol. 2024;61:1491\u20134. https:\/\/doi.org\/10.1007\/s00592-024-02331-z.","journal-title":"Acta Diabetol"},{"key":"2279_CR89","doi-asserted-by":"publisher","DOI":"10.47363\/JDRR\/2024(6)178","author":"B Patel","year":"2024","unstructured":"Patel B, Healy A. Positive pregnancy outcome following first trimester dulaglutide exposure in a women with type 2 diabetes and PCOS: a case report. J Diabetes Res Rev Rep. 2024. https:\/\/doi.org\/10.47363\/JDRR\/2024(6)178.","journal-title":"J Diabetes Res Rev Rep."},{"key":"2279_CR90","doi-asserted-by":"publisher","DOI":"10.1097\/og9.0000000000000077","volume":"2","author":"D Abushanab","year":"2025","unstructured":"Abushanab D, Mohammed HR, Abdul Rouf PV, Thomas B, Al-Badriyeh D, Elkassem W, et al. Exposure to high-dose liraglutide in a pregnant woman with obesity. O&G Open. 2025;2:e077. https:\/\/doi.org\/10.1097\/og9.0000000000000077.","journal-title":"O&G Open"},{"key":"2279_CR91","unstructured":"Ozdemir H, Pektas B, Erkoseoglu I, Kerimoglu G, Kadioglu M, Osmanagaoglu M, et al. Safety of liraglutide during pregnancy: a case report.  Poster 49. 36th ENTIS Conference, ENTIS2025 conference, Thessaloniki, Greece. 2025.  https:\/\/www.entis-org.eu\/wp-content\/uploads\/2025\/09\/Entis2025-Prog.pdf. Accessed 12 Dec 2025."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02279-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02279-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02279-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:35:42Z","timestamp":1772764542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02279-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02279-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Penelope Fotheringham, Richard G. McGee, Ruby Chang, and David Simmons contributed to the conceptualisation of the review. Penelope Fotheringham, Richard G. McGee and Ruby Chang conducted the literature review and analysis. All authors (Penelope Fotheringham, Richard G. McGee, Ruby Chang, Debra Kennedy, and David Simmons) contributed to drafting and editing the manuscript and approved the final version. David Simmons was invited to submit the review, provided overall supervision, and acts as guarantor of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}